Citadel Advisors
HSCS icon

Citadel Advisors’s Heart Test Laboratories HSCS Stock Holding History

Citadel Advisors’s Portfolio HSCS Stock Details HSCS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.4K Buy
+14,488
New +$29.7K ﹤0.01% 13253
2025
Q3 		– Sell
-18,684
Closed -$70.1K – 13347
2025
Q2 		$70.1K Buy
+18,684
New +$65.3K ﹤0.01% 11588
2024
Q2 		– Sell
-1,231
Closed -$14.4K – 14756
2024
Q1 		$14.4K Buy
1,231
+922
+298% +$12.1K ﹤0.01% 13247
2023
Q4 		$5.28K Buy
309
+3
+1% +$74 ﹤0.01% 13440
2023
Q3 		$13.2K Buy
+306
New +$23.7K ﹤0.01% 12930
2022
Q3 		– Sell
-234
Closed -$44K – 13035
2022
Q2 		$44K Buy
+234
New +$45.2K ﹤0.01% 12012

Other funds holding HSCS

TA
TFB Advisors Overland Park, Kansas $227M AUM 26.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ASW
Astoria Strategic Wealth Conroe, Texas $438M AUM 16.79% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors's HSCS Position: Q2 2026 in Review

Citadel Advisors opened a new position in Heart Test Laboratories (HSCS) in Q2 2026: 14,488 shares worth $36.4K. The stake represents ﹤0.01% of the portfolio and ranks #13253 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in HSCS as recently as Q2 2025.

Citadel Advisors first reported a position in HSCS in Q2 2022 and has held it in 6 quarters since. The position peaked at $70.1K in Q2 2025. 16 funds tracked by Wall St. Rank hold HSCS as of Q2 2026.

  • Citadel Advisors held 14,488 shares of Heart Test Laboratories worth $36.4K as of Q2 2026.
  • Heart Test Laboratories was a new Citadel Advisors position in Q2 2026.
  • Heart Test Laboratories made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13253 holding.
  • Citadel Advisors first reported a position in Heart Test Laboratories in Q2 2022 and has held it in 6 quarters since.
  • Citadel Advisors's Heart Test Laboratories position peaked at $70.1K in Q2 2025.
  • 16 funds tracked by Wall St. Rank held Heart Test Laboratories as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.